What Is Trigeminal Neuralgia and Where Does It Come From?
The trigeminal nerve (the fifth cranial nerve) is the main nerve carrying sensation from the face. In classic trigeminal neuralgia, most pain attacks are explained by a blood vessel (usually the superior cerebellar artery) compressing the nerve at its exit from the brainstem and damaging its protective sheath; this is called 'neurovascular compression'. The pain typically occurs on one half of the face — around the cheek, jaw or eye — triggered by chewing, talking, brushing teeth, wind or a light touch. In some patients an underlying disorder such as multiple sclerosis or, rarely, a tumour may be present; for this reason contrast-enhanced thin-slice MRI is important in diagnosis. A correct diagnosis requires distinguishing it from similar facial pains (dental pain, atypical facial pain, cluster headache), because treatment is entirely different.
Medication First: First-Line Treatment
The first step in treating trigeminal neuralgia is almost always medication. Carbamazepine and oxcarbazepine are the drugs with the best-proven efficacy in this disorder and provide marked initial relief in the great majority of patients. In some patients drugs such as baclofen, lamotrigine or gabapentin are added. However, drug treatment has limits: efficacy may decline over time, and as the dose rises side effects such as dizziness, imbalance, drowsiness and low sodium may appear. If adequate pain control cannot be achieved with medication, or side effects impair quality of life, the next step — surgical and interventional methods — is evaluated. It is wrong to stop a medication that should be continued too early; medication changes are made under a physician's supervision.
Microvascular Decompression (MVD): Surgery Addressing the Cause
Microvascular decompression is the only method that aims to directly eliminate the cause in classic trigeminal neuralgia due to neurovascular compression. Through a small craniotomy behind the ear, under the microscope, the vessel compressing the nerve near the brainstem is identified and a small cushion (usually Teflon) is placed between the nerve and the vessel to relieve the compression; the nerve is neither cut nor damaged. The greatest advantage of MVD is that, in well-selected patients, it provides high and long-lasting pain relief without leaving facial numbness. Because it is an operation performed under general anaesthesia working near the brainstem, it carries risks such as hearing loss, facial weakness and CSF leak; for this reason it is considered first especially in patients in good general health, with a long life expectancy and clear vascular compression on imaging. The procedure typically takes 2–3 hours; a hospital stay of 3–5 days and a few weeks of recovery are usual.
Gamma Knife and Percutaneous Methods
For patients who are not suitable for surgery, are of advanced age, are unsuitable for anaesthesia because of comorbidities, or who prefer not to undergo MVD, there are other options that reduce pain in a targeted way. Gamma Knife radiosurgery is an incision-free, single-session method that delivers highly focused radiation to the trigeminal nerve; relief usually begins within a few weeks to months and gives good results in suitable patients, but there is a possibility of facial numbness and pain recurring over time. Percutaneous methods (radiofrequency rhizotomy, balloon compression, glycerol injection) reach the nerve via a needle through the cheek and disrupt pain conduction; they act quickly and are preferred especially in cases due to multiple sclerosis or unsuitable for surgery, but carry the possibility of facial numbness and recurrence. Which method is appropriate is determined by the patient's age, general condition, MRI findings and preferences; there is no single 'best' method — it is chosen individually.
Risks and Realistic Expectations
In treating trigeminal neuralgia each method has its own benefits and risks, which must be discussed honestly. Drug treatment carries side effects and efficacy that declines over time; MVD carries general surgical risks and, though rare, effects on the hearing/facial nerve; Gamma Knife and percutaneous methods carry the possibility of facial numbness and recurrence of pain. In general MVD provides the longest-lasting relief in suitable patients, while Gamma Knife and percutaneous methods are less invasive but may have a higher recurrence rate. No method guarantees 'lifelong, definitive freedom from pain'; pain may recur after a time and, if needed, treatment can be repeated or the method changed. Expectations are shared openly after MRI findings and the patient's general condition have been assessed. What matters is making the correct diagnosis and choosing together the method that offers the most benefit with the least risk for the patient.